Vascular access and infection prevention: a practice overview

Intravenous therapy is so routine that its risks can be easy to overlook. BD frames vascular access management as a continuum of care running from patient assessment through to device removal, and notes that up to 90 percent of hospital inpatients require IV therapy, with a single vascular access device potentially seeing a large number of separate touches across its dwell time and across multiple clinicians and shifts.

The complications BD lists across that journey are the ones familiar to every ward: catheter-related bloodstream infection, occlusion, dislodgement and phlebitis. BD describes these as a major cause of vascular access device failure and points to contributing factors such as breaking asepsis during insertion or maintenance, non-intact dressings, poor site selection, inadequate securement, and improper flushing or clamping sequences.

Skin preparation is the first controllable variable. BD ChloraPrep patient preoperative skin preparation is described by the company as delivering standardised, powerful and persistent antimicrobial protection, and BD states that the product is backed by more than 60 clinical studies and has been used by healthcare providers for more than 21 years. BD also reports that in a recent clinical study, BD ChloraPrep preoperative skin antiseptic demonstrated antimicrobial persistence for at least seven days.

BD lists the BD ChloraPrep with Sterile Solution applicator range in 1 mL, Frepp 1.5 mL, 3 mL, 10.5 mL and 26 mL sizes, which is intended to match applicator volume to the coverage area required. From a governance perspective, applicator sizing matters because it removes the temptation to improvise coverage with an applicator that is too small for the field, and because it supports a consistent, auditable technique across departments.

Once a line is in place, maintenance determines how long it lasts. BD notes that flushing helps maintain patency of the line and reduce the risk of complications including occlusion and premature catheter failure, and describes flushing before and after medication as a strongly recommended step that helps prevent contact between incompatible medicines and ensures the entire dose is delivered. The BD PosiFlush prefilled flush syringe family is BD's product answer to that step, with the company highlighting design details such as a three-rib stopper intended to reduce the likelihood of syringe-induced catheter reflux.

For hospital teams, the value of these product categories is realised through protocol rather than purchase. Written bundles covering hand hygiene, skin antisepsis, dressing selection and change intervals, scrub-the-hub practice, flushing regimens and daily review of line necessity are what convert individual devices into a reliable infection-prevention programme. Clinical use of any device must follow the manufacturer's official instructions for use. Detailed specifications and available configurations are available on request, and Azmed Devices provides documentation, tender support and supply coordination for BD technologies in Azerbaijan.

Manufacturer statements in this article are drawn from BD's official website. See https://www.bd.com/en-us/products-and-solutions/solutions/vascular-access-management, https://www.bd.com/en-us/products-and-solutions/products/product-brands/chloraprep and https://www.bd.com/en-us/products-and-solutions/products/product-families/bd-posiflush-pre-filled-saline-syringe. This article is general educational content and is not clinical guidance; product availability in Azerbaijan is subject to local registration.